Medipost's 'Cartistem' Clinical Patient Long-term Follow-up Paper Selected as Best Paper by US OJSM
[Asia Economy Reporter Lee Gwan-joo] Medipost announced on the 18th that the clinical phase 3 study paper on the 48-week and 5-year long-term efficacy follow-up after surgery of the knee osteoarthritis treatment 'Cartistem' was selected as the Best Paper of last year by the Orthopaedic Journal of Sports Medicine (OJSM).
OJSM is the SCI-level official journal of the American Orthopaedic Society for Sports Medicine (AOSSM), which celebrated its 50th anniversary this year. The Best Paper Award was selected by reviewing all papers published in OJSM last year, choosing a total of 18 papers across three categories. Among them, the Cartistem long-term follow-up paper was the first domestic paper to be selected as the Best Paper in the academic paper category.
This paper includes the results of long-term follow-up at 48 weeks and 5 years after administration for a total of 89 patients who participated in the phase 3 clinical trial. The 5-year long-term follow-up results demonstrated that the Cartistem treatment group showed significant and sustained improvement compared to the microfracture control group in efficacy evaluation indicators such as knee pain and stiffness, physical function improvement over time (WOMAC), subjective pain relief (100 mm VAS), and joint function improvement (IKDC). Furthermore, the long-term cartilage regeneration effect was also confirmed. Notably, meaningful results were observed even in patients with severe cartilage defects and elderly patients aged 60 or older.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- 'Still Hesitant? If You're Wondering Whether KOSPI Will Rise, This Is the Number You Must Watch [Weekend Money]'
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
A Medipost official stated, “Cartistem has been recognized overseas as a definitive treatment option for severe and elderly knee osteoarthritis patients by improving knee function and pain in the long term through the regenerative effect on damaged cartilage,” adding, “We will accelerate overseas clinical trials and do our best to make Cartistem a global blockbuster.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
